DISCONTINUATION OF DENGVAXIA AND ONGOING MONITORING OF DENGUE VACCINES

NOTICE PAPER NO. 1002
NOTICE OF QUESTION FOR WRITTEN ANSWER
FOR THE SITTING OF PARLIAMENT ON OR AFTER 09 SEPTEMBER 2026

Name and Constituency of Member of Parliament
Ms He Ting Ru
MP for Sengkang GRC

Question No. 1691
To ask the Coordinating Minister for Social Policies and Minister for Health given that Dengvaxia has been discontinued by the manufacturer (a) what support and advisory arrangements are in place for patients who have already been vaccinated or who are mid-course in the vaccination series, including access to remaining doses, clinical follow-up, and risk counselling; and (b) whether any alternatives are being explored.

Answer 

1        The manufacturer for Dengvaxia has decided to discontinue the vaccine due to low global demand. No further follow up was required for individuals who had previously completed the recommended doses of Dengvaxia, since the discontinuation was not due to safety concerns. 

2        When the discontinuation of Dengvaxia was announced in 2025, the manufacturer informed healthcare service providers of the stock availability, who could then in turn contact patients who had their first dose or second dose, to advise them on completing the vaccination series.

3        There are no new updates following the response to a parliamentary question on the same topic dated 4 February 2026. The Ministry of Health and relevant agencies will continue to monitor the development of dengue vaccines.